Last reviewed · How we verify

NCT07009808

Nalbuphine Dosing and Its Impact on Anxiety and Depression in Ectopic Pregnancy Surgery

Not yet recruiting NA Last updated 8 June 2025
What this trial tests

NA trial testing Nalbuphine 0.20mg/ml(total 30 mg) in Ectopic Pregnancy in 165 participants. Not yet recruiting.

Timeline
20 June 2025
Primary endpoint
22 October 2025
30 October 2025

Quick facts

Lead sponsorChengdu Jinjiang Maternity and Child Health Hospital
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment165
Start date20 June 2025
Primary completion22 October 2025
Estimated completion30 October 2025

Drugs / interventions tested

Conditions studied

Sponsor

Chengdu Jinjiang Maternity and Child Health Hospital

Who can join

18 and older, female only, with Ectopic Pregnancy or Anxiety. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This prospective, randomized, controlled study aims to evaluate the impact of different doses of nalbuphine on anxiety and depression in patients undergoing surgery for ectopic pregnancy. Ectopic pregnancy, which occurs in approximately 2% of all pregnancies, often requires surgical intervention, leading to potential psychological distress such as anxiety and depression in affected women. Effective postoperative pain management is essential to enhance recovery and reduce emotional disturbances. The study will involve 165 eligible patients diagnosed with ectopic pregnancy at Jinjiang District Maternal and Child Health Hospital. Participants will be randomly assigned to three groups, each receiving a different concentration of nalbuphine combined with metoclopramide for postoperative analgesia. The primary outcome will focus on changes in anxiety and depression scores measured on postoperative day three, while secondary outcomes will assess pain levels, the use of patient-controlled analgesia (PCA), the necessity for rescue analgesics, and the occurrence of adverse reactions. Sample size calculations suggest that at least 165 participants are required to achieve adequate statistical power. Data will be analyzed using SPSS 25.0 software, with results expected to provide insights into the effectiveness of nalbuphine in improving postoperative recovery and mental health in women experiencing ectopic pregnancy. The study has received ethical approval and is funded by the Chengdu Medical Research Projects (No. 2023465, 2022548, and 2023304).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Ectopic Pregnancy

Currently open trials in the same condition.

Other Chengdu Jinjiang Maternity and Child Health Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07009808.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing